Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Share subscriptions based on stock option 2013B

CapMan Plc Stock Exchange Release         11 February 2019 at 10.00 a.m. EET Share subscriptions based on stock option 2013B Between 1 December 2018 and 21 January 2019, a total of 201,803 CapMan Plc new shares have been subscribed for with the company's stock options 2013B. The entire subscription price of EUR 167,496.49 shall be recorded into the invested non-restricted equity fund. As a result of the subscriptions, the number of CapMan shares increases to 147,343,966. The shares subscribed for under the stock options have been registered in the Trade Register on 11 February

Selvaag Bolig ASA: Invitation to presentation of fourth quarter 2018 results

Selvaag Bolig ASA will publish its fourth quarter 2018 results Wednesday 13 February at 07:00 am CET.The quarterly report and the presentation materials will be available on the company's website, www.selvaagboligasa.no/en and www.newsweb.no, as well as news wires. CEO Olav H. Selvaag and CFO Sverre Molvik will present the company's results at 08:30 am CET at Høyres Hus, Stortingsgaten 20 in Oslo. A light breakfast will be served from 08:00. The presentation will be held in Norwegian and transferred via live webcast. The link to the webcast can be found on the company's website. It

Karo Intressenter’s proposals ahead of the Extraordinary General Meeting in Karo Pharma on 14 February 2019

EQT VIII[1] through Karo Intressenter AB (”Karo Intressenter”) proposes, ahead of the Extraordinary General Meeting in Karo Pharma Aktiebolag (”Karo Pharma”) on 14 February 2019 that the Board Member Håkan Åström is reelected and that Bo Jesper Hansen, Erika Henriksson, Vesa Koskinen, Christoffer Lorenzen and Åsa Riisberg are elected as new Board Members with Bo Jesper Hansen as Chairman of the Board.Karo Pharma has, at the request of Karo Intressenter, convened an Extraordinary General Meeting at 15:00 on 14 February 2019 to, inter alia, consider the election of a new Board of Directors.

Redwood Pharma to Attend BIO-Europe 2019, Mar. 25 – 27 in Vienna for Partnering Discussions

Redwood Pharma will be attending BIO-Europe 2019 in Vienna, Mar. 25 – 27 to meet and continue discussions with potential pharmaceutical partners regarding co-development and licensing of RP101, the Company’s therapy to treat chronic dry eye disease in postmenopausal women and the IntelliGel drug delivery platform.RP101 is the Company’s lead program for the development of a novel treatment of chronic dry eye disease in postmenopausal women. The active substance is an endogenous small molecule already proven safe and effective in two Phase II clinical trials conducted in the US. The active

Scout Gaming enters Brazil with Jogajà

Scout Gaming has entered into a license agreement with Jogajà. The agreement gives Jogajà full access to Scout Gaming’s full Fantasy Sports platform."We continue to build our global network and are excited about entering South America. We are experiencing a global increasing interest in Fantasy Sports gradually”, comments Scout Gaming CEO Andreas Ternström. Jogaja has recruited a team with wide experience from the gambling industry, led by Jacob Lindorff with background from Expekt, Betway and Bonnier Gaming. Jogaja is a startup backed by Swedish venture capitalists with previous

NeuroVive is supplied with approximately MSEK 99.0 in share issue proceeds

Lund, February 11, 2019 - NeuroVive Pharmaceutical AB (publ) ("NeuroVive" or the "Company") (Nasdaq Stockholm: NVP, OTCQX: NEVPF) today announced the outcome of the preferential rights issue of shares, approved at the Extraordinary General Meeting on January 17, 2019 ("Rights Issue"). The Rights Issue has been subscribed to approximately MSEK 74.5, corresponding to a subscription ratio of approximately 60.2 percent, which means that approximately 19.8 percent of the total volume of the Rights Issue was allocated to guarantors. Through the Rights Issue, NeuroVive will thus raise approximately

Follicum selects novel peptide drug candidate for the treatment of diabetes and protection of beta cells

Follicum AB ("Follicum" or "the company"), a biotech company focusing on research and development of peptide-based drugs, today reports that a drug candidate has been selected for the treatment of diabetes and protection of beta cells. The drug candidate has shown unique effects in both in vitro and in vivo-models, including diabetes-related complications. The drug will now be tested in a preclinical program prior to upcoming clinical trials. The choice of drug candidate represents a significant milestone for both Follicum and for the diabetes project which is part of a large collaborative

Presentation of Probi’s Q4 report 2018

Probi’s report for the fourth quarter 2018 will be published on Wednesday, 13 February at 8.00 a.m. CET. In conjunction with this, analysts, investors and media are invited to an audiocast telephone conference on the same day at 10.00 a.m., where CEO Tom Rönnlund and CFO Henrik Lundkvist will present and comment on the report. The presentation and presentation material can be obtained via www.probi.com  or https://tv.streamfabriken.com/probi-q4-2018 The presentation can also be followed via a telephone conference on the following telephone number:Sweden: +46 8

The performance of the core methods in food microbiology validated

The core methods of food microbiology have been standardised for years, and financially significant decisions on the safety and marketability of products are made on the basis of studies conducted according to these standards. Legislation, such as the Microbiological Criteria Regulation, requires the use of certain standard procedures in, for example, Salmonella, Listeria and Campylobacter analyses. The Finnish Food Authority’s microbiology unit has played an important role in the development of standards for the procedures, including participation in the international validation studies for

Follicum selects novel peptide drug candidate for the treatment of diabetes and protection of beta cells

Follicum AB ("Follicum" or "the company"), a biotech company focusing on research and development of peptide-based drugs, today reports that a drug candidate has been selected for the treatment of diabetes and protection of beta cells. The drug candidate has shown unique effects in both in vitro and in vivo-models, including diabetes-related complications. The drug will now be tested in a preclinical program prior to upcoming clinical trials. The choice of drug candidate represents a significant milestone for both Follicum and for the diabetes project which is part of a large collaborative

Nexam Chemical publish a video interview with the new CEO Johan Arvidsson

A video has been published on Nexam Chemicals website where the company´s new CEO Johan Arvidsson are interviewed regarding his new role in the company. The interview, in Swedish, is available on www.nexamchemical.com  under presentations.Note: This press release has been translated from Swedish. The Swedish text shall govern for all purposes and prevail in case of any discrepancy with the English version. For further information please contact: Lennart Holm, Chairman of the Board, +46-706 30 85 62, lennart.holm@nexamchemical.com

Successful refinancing of its Nordic Logistics and Industrial Real Estate Portfolio with new loan facility from a leading global insurance institution

Delivering value enhancing active asset management initiativesUK / Nordics, 11 February 2019 – Round Hill Capital (“Round Hill”), a leading specialist real estate investment, development and asset management firm together with StepStone Group Real Estate LP (“StepStone Real Estate”), a leading private markets firm, today announces that they have completed the multi-currency refinancing of the acquisition debt secured against their Nordic logistics and industrial real estate portfolio (the “Portfolio”), which comprises 327,649 sqm across 13 assets in Sweden, Norway and Denmark. The new

What will the scientific community of colors look like tomorrow? In conversation with two chemistry professionals from Tikkurila’s Research and Development team.

It goes without saying that women are intelligent, tough and capable of changing the world. Despite that and the huge progress that has already been made, a big gender gap still exists at all levels of science around the world. That’s why, on February 11, we celebrate the International Day of Women and Girls in Science organized by United Nations. Today, we raise a toast to the diverse workforce of Tikkurila by interviewing two steadfast professionals: Heidi Helkamo, RDI Director Tikkurila Finland and Minna Perttu, a researcher from our research and development department. Behind

CapMan Real Estate and Conorin establish a multipurpose properties concept for small and medium-sized companies

CapMan Real Estate press release    11 February 2019 at 9.00 a.m. EET CapMan Real Estate and Conorin establish a multipurpose properties concept for small and medium-sized companies CapMan Nordic Real Estate II fund and Conorin Oy, a company specialised in real estate development, have established a multipurpose properties concept,”Monitoimitilat.fi,” which rents modular and transformable commercial properties in growth centres. The joint venture to establish a portfolio of light industrial multipurpose properties combines CapMan Real Estate’s institutional investor community and

Webcast with Teleconference, Q4 / 2018

Nitro Games to host a Webcast with Teleconference on Monday 18 February 2019 09:30 Swedish time.Nitro Games Oyj year end report for January - December 2018 will be released on Monday 18 February 2019. After the release of the report, the Company will do a presentation. Participants can join this presentation by a Webcast or Teleconference. February 18 2019 09:30 (Europe/Stockholm) Details of event: https://financialhearings.com/event/11656 Language: English Activity: Webcast with Teleconference Webcast: https://tv.streamfabriken.com/nitro-games-q4-2018 Teleconference: Dial-

Gaming Innovation Group reports Q4 2018

Gaming Innovation Group Inc. (GiG) reports €39.9 million in revenues in Q4 2018 and an EBITDA of €5.0 million. One-off items adversely impacted EBITDA by €1.8m in Q4 2018. Excluding one-off costs, EBITDA was €6.9m in Q4 and €18.9m for the full year 2018. “In Q4, we matched our previous all-time-high in revenues and for the full year 2018, we grew revenues and EBITDA with nearly 30% over 2017. After investing around €16m into tech and product development in 2018, we have now closed the circle and are offering products and services across all major verticals in the iGaming value chain.

Johan Arvidsson appointed new CEO of Nexam Chemical

The board of directors in Nexam Chemical Holding AB has appointed Johan Arvidsson as the new CEO of the company. Johan, who has worked as CSO at Nexam Chemical since 2016, will take over as new CEO on February 15, 2019. Former CEO Anders Spetz has chosen, after four intensive years, to leave his position to start his own business.“I am very pleased to be able to present Johan Arvidsson as the successor to Anders Spetz. Johan has, during the last two years, successfully been responsible for sales within Nexam Chemical and been a member of the company´s management team. He is an experienced

Share buy-backs in Nordic Waterproofing during week 6, 2019

During the period February 4, 2019, until and including February 8, 2019, Nordic Waterproofing Holding A/S has repurchased in total 17,917 own shares (ISIN: DK0060738409). The share buy-backs form part of the SEK 18 million share buy-back program that Nordic Waterproofing announced on December 20, 2018. The share buy-back program, which runs between December 20, 2018, and March 29, 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 (“MAR”) and the Commission Delegated Regulation (EU) No 2016/1052 (the “Safe Harbour Regulation”).During the period

New store concept - KappAhl Kids makes an entrance

KappAhl Kids is here! On 28 February, fashion chain KappAhl will launch a new store concept, with KappAhl Kids opening its doors to the public at the Ringen shopping centre in Södermalm, Stockholm.“KappAhl’s children’s range is held in high regard, and represents a growing part of our sales. With KappAhl Kids, we are testing out new ways of making it even more visible,” says Peter Andersson, KappAhl’s CFO and acting CEO.KappAhl Kids is the fashion chain’s second free-standing concept, after Newbie Store. The store will be showcasing the entirety of KappAhl’s popular children’s range, and

Invitation to telephone conference on 15 February to present Eastnine’s Year-end Report 2018

Eastnine's Year-end report 2018 will be published on Friday, 15 February 2019 at 08.00 a.m. CET. The report will be presented at a telephone conference by Kestutis Sasnauskas, CEO at Eastnine, and Mattias Lundgren, Interim CFO at Eastnine. Date:                        Friday, 15 February 2019 Time:                        10.00 a.m. CET Dial-in numbers:  +46 8 566 42 661 (SE), +44 203 194 05 44 (UK), + 1 855 269 26 04 (US) Please dial in a few minutes before the conference starts. The presentation for the telephone conference will be made available on www.eastnine.com no later

PHI and BioSpherix expand marketing partnership after scientific evaluation

In June 2018, Phase Holographic Imaging (PHI) and BioSpherix Medical entered a collaboration agreement, aiming to co-market the companies’ complementary product lines. BioSpherix  develops and market advanced hermetically sealed cell incubators for the control and optimization of cell culture environments. Since most cell analysis instruments are not adapted to cope with the demanding environment within cell incubators, analytical instruments are generally placed outside the incubator. Consequently, the cells need to be moved from the incubator into the

Conference call regarding Elekta’s Q3 report for 2018/19

STOCKHOLM, February 11, 2019 – Elekta (EKTA-B.ST) will publish its Q3 report for 2018/19 on February 22, as per: · The report will be published at 07:30 CET. · Elekta will host a telephone conference starting at 10:00 CET with Richard Hausmann, President and CEO, and Gustaf Salford, CFO. To take part in the conference call, please dial in about five minutes in advance. · UK dial-in number: +44 (0) 333 300 9265 · US dial-in number: +1 646 722 4902 · Swedish dial-in number: +46 (0) 8 505 583 50 The telephone conference will also be broadcasted live online, through the

Share buy-backs in Telia Company during week 6 2019

During the period February 4, 2019, until February 8, 2019, Telia Company AB (publ) (LEI code 213800FSR9RNDUOTXO25) has repurchased in total 1,997,000 own shares (ISIN: SE0000667925). The share buy-backs form part of the SEK 5 billion share buy-back programme that Telia Company announced on April 20, 2018. The share buy-back programme, which runs between April 23, 2018, and March 22, 2019, is being carried out in accordance with the Market Abuse Regulation (EU) No 596/2014 ("MAR") and the Commission Delegated Regulation (EU) No 2016/1052 (the "Safe Harbour Regulation").During the period

There are no items matching the current filter
There are no more items matching the current filter
Back to top